APOE and Alzheimer disease: In our and previous studies evaluating blood-biomarker models23–25, including age and APOE ε4 status—known relevant risk factors of Aβ positivity40,41—led to more discriminative models with a higher spread in predictions, which can help in supporting better screening decisions, and such models will probably become more common in AD diagnostics.